Search
Uniqure NV
QUREAdd to Watchlist
42.760USD
-2.520-5.57%
Close 09-23 16:00（ET）
2.97BMarket Cap
LossP/E TTM
After-hours 17:47 (ET)42.780USD-0.030-0.07%
After-hours 17:47 (ET)About Uniqure NV Company
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Uniqure NV Profile
Ticker SymbolQURE
Company nameUniqure NV
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Number of employees209
Security typeOrdinary Share
Fiscal year-endFeb 05
AddressPaasheuvelweg 25a
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1105 BP
Phone31202406000
Websitehttps://www.uniqure.com/
Ticker SymbolQURE
IPO dateFeb 05, 2014
CEOKapusta (Matthew)
Company Executives of Uniqure NV
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
47.69K
-0.17%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
47.69K
-0.17%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
47.69K
-0.17%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
42.31K
-12.38%
Dr. Walid Abi-Saab, M.D.
Dr. Walid Abi-Saab, M.D.
Chief Medical Officer
Chief Medical Officer
42.30K
-50.67%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
121.51K
+23.43%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
47.69K
-0.17%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
47.69K
-0.17%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
47.69K
-0.17%
FAQs
Who are the top five shareholders of Uniqure NV?
The top five shareholders of Uniqure NV are: Mr. Christian Klemt, CPA
How many institutions hold shares of Uniqure NV (QURE)?
As of 2026Q1, 481 institutions hold shares of Uniqure NV, with a combined market value of approximately 65.80M, accounting for 104.34% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1601871.00.